These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 15500006)

  • 1. Screening for small molecule inhibitors of insulin-like growth factor receptor (IGF-1R) kinase: comparison of homogeneous time-resolved fluorescence and 33P-ATP plate assay formats.
    Wang Y; Malkowski M; Hailey J; Turek-Etienne T; Tripodi T; Pachter JA
    J Exp Ther Oncol; 2004 Jul; 4(2):111-9. PubMed ID: 15500006
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of three approaches for inhibiting insulin-like growth factor I receptor and their effects on NSCLC cell lines in vitro.
    Cosaceanu D; Carapancea M; Alexandru O; Budiu R; Martinsson HS; Starborg M; Vrabete M; Kanter L; Lewensohn R; Dricu A
    Growth Factors; 2007 Feb; 25(1):1-8. PubMed ID: 17454144
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of an inhibitor of insulin-like growth factor 1 receptor activation: implications for cellular potency and selectivity over insulin receptor.
    Wood ER; Shewchuk L; Hassel A; Nichols J; Truesdale AT; Smith D; Carter HL; Weaver K; Barrett G; Leesnitzer T; Alvarez E; Bardera AI; Alamillo A; Cantizani J; Martin J; Smith GK; Jensen DE; Xie H; Mook R; Kumar R; Kuntz K
    Biochem Pharmacol; 2009 Dec; 78(12):1438-47. PubMed ID: 19665448
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sensitivity of breast cancer cell lines to the novel insulin-like growth factor-1 receptor (IGF-1R) inhibitor NVP-AEW541 is dependent on the level of IRS-1 expression.
    Mukohara T; Shimada H; Ogasawara N; Wanikawa R; Shimomura M; Nakatsura T; Ishii G; Park JO; Jänne PA; Saijo N; Minami H
    Cancer Lett; 2009 Sep; 282(1):14-24. PubMed ID: 19345478
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insulin-like growth factor-1 receptor acts as a growth regulator in synovial sarcoma.
    Friedrichs N; Küchler J; Endl E; Koch A; Czerwitzki J; Wurst P; Metzger D; Schulte JH; Holst MI; Heukamp LC; Larsson O; Tanaka S; Kawai A; Wardelmann E; Buettner R; Pietsch T; Hartmann W
    J Pathol; 2008 Dec; 216(4):428-39. PubMed ID: 18855347
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RT-PCR-based tyrosine kinase display profiling of canine melanoma: IGF-1 receptor as a potential therapeutic target.
    Thamm DH; Huelsmeyer MK; Mitzey AM; Qurollo B; Rose BJ; Kurzman ID
    Melanoma Res; 2010 Feb; 20(1):35-42. PubMed ID: 19949352
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of hematologic malignancies and solid tumors by inhibiting IGF receptor signaling.
    Mitsiades CS; Mitsiades N
    Expert Rev Anticancer Ther; 2005 Jun; 5(3):487-99. PubMed ID: 16001956
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insulin-like growth factor type-I receptor-dependent phosphorylation of extracellular signal-regulated kinase 1/2 but not Akt (protein kinase B) can be induced by picropodophyllin.
    Vasilcanu R; Vasilcanu D; Sehat B; Yin S; Girnita A; Axelson M; Girnita L
    Mol Pharmacol; 2008 Mar; 73(3):930-9. PubMed ID: 18070930
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Luteolin inhibits insulin-like growth factor 1 receptor signaling in prostate cancer cells.
    Fang J; Zhou Q; Shi XL; Jiang BH
    Carcinogenesis; 2007 Mar; 28(3):713-23. PubMed ID: 17065200
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective inhibition of SCLC growth by the A12 anti-IGF-1R monoclonal antibody correlates with inhibition of Akt.
    Yeh J; Litz J; Hauck P; Ludwig DL; Krystal GW
    Lung Cancer; 2008 May; 60(2):166-74. PubMed ID: 18006183
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ATP non-competitive IGF-1 receptor kinase inhibitors as lead anti-neoplastic and anti-papilloma agents.
    Steiner L; Blum G; Friedmann Y; Levitzki A
    Eur J Pharmacol; 2007 May; 562(1-2):1-11. PubMed ID: 17376430
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insulin-like growth factor 1 is a potent stimulator of cervical cancer cell invasiveness and proliferation that is modulated by alphavbeta3 integrin signaling.
    Shen MR; Hsu YM; Hsu KF; Chen YF; Tang MJ; Chou CY
    Carcinogenesis; 2006 May; 27(5):962-71. PubMed ID: 16400188
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of ubiquitination in IGF-1 receptor signaling and degradation.
    Sehat B; Andersson S; Vasilcanu R; Girnita L; Larsson O
    PLoS One; 2007 Apr; 2(4):e340. PubMed ID: 17406664
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro and in vivo antitumor effects of the dual insulin-like growth factor-I/insulin receptor inhibitor, BMS-554417.
    Haluska P; Carboni JM; Loegering DA; Lee FY; Wittman M; Saulnier MG; Frennesson DB; Kalli KR; Conover CA; Attar RM; Kaufmann SH; Gottardis M; Erlichman C
    Cancer Res; 2006 Jan; 66(1):362-71. PubMed ID: 16397250
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nordihydroguaiaretic acid (NDGA) inhibits the IGF-1 and c-erbB2/HER2/neu receptors and suppresses growth in breast cancer cells.
    Youngren JF; Gable K; Penaranda C; Maddux BA; Zavodovskaya M; Lobo M; Campbell M; Kerner J; Goldfine ID
    Breast Cancer Res Treat; 2005 Nov; 94(1):37-46. PubMed ID: 16142439
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery and SAR of thiazolidine-2,4-dione analogues as insulin-like growth factor-1 receptor (IGF-1R) inhibitors via hierarchical virtual screening.
    Liu X; Xie H; Luo C; Tong L; Wang Y; Peng T; Ding J; Jiang H; Li H
    J Med Chem; 2010 Mar; 53(6):2661-5. PubMed ID: 20178321
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insulin-like growth factor 1 receptor signaling regulates skin development and inhibits skin keratinocyte differentiation.
    Sadagurski M; Yakar S; Weingarten G; Holzenberger M; Rhodes CJ; Breitkreutz D; Leroith D; Wertheimer E
    Mol Cell Biol; 2006 Apr; 26(7):2675-87. PubMed ID: 16537911
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The insulin-like growth factor receptor 1 is a promising target for novel treatment approaches in neuroendocrine gastrointestinal tumours.
    Höpfner M; Baradari V; Huether A; Schöfl C; Scherübl H
    Endocr Relat Cancer; 2006 Mar; 13(1):135-49. PubMed ID: 16601284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibitors of insulin-like growth factor-1 receptor tyrosine kinase are preferentially cytotoxic to nutrient-deprived pancreatic cancer cells.
    Momose I; Kunimoto S; Osono M; Ikeda D
    Biochem Biophys Res Commun; 2009 Feb; 380(1):171-6. PubMed ID: 19166817
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epidermal growth factor induces insulin receptor substrate-2 in breast cancer cells via c-Jun NH(2)-terminal kinase/activator protein-1 signaling to regulate cell migration.
    Cui X; Kim HJ; Kuiatse I; Kim H; Brown PH; Lee AV
    Cancer Res; 2006 May; 66(10):5304-13. PubMed ID: 16707456
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.